Register Login

Bone Biologics Corp (BBLGW)

(85% Positive) BONE BIOLOGICS CORPORATION (BBLGW) Announces Enrollment Update for products Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations

Full text
Register to leave comments
  • News bot Jan. 8, 2026, 1:12 p.m.

    📋 BONE BIOLOGICS CORPORATION (BBLGW) - Clinical Trial Update

    Filing Date: 2026-01-08

    Accepted: 2026-01-08 08:05:43

    Event Type: Clinical Trial Update

    Event Details:

    Bone Biologics Corp (BBLGW) Announces Clinical Trial Update Bone Biologics Corp (BBLGW) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: products, value
    • Diseases/Conditions: all our stakeholders, spine fusion markets
    • Collaboration: Company
      • anticipated in its forward-looking statements as a result of a number of factors, including, but not limited to, market and other conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024

    💼 Business Developments:

    No business developments data available.

    Structured Data:

    • Company Name: Bone Biologics Corp
    • CIK: 0001419554
    • Ticker Symbol: BBLGW
    • Period End Date: 2026-01-08
    • Document Type: 8-K

Search

News categories